Biotech Values

[go seek]

Given how this suit has developed over the past several weeks and knowing the history of Momenta and Amphastar as it relates to their respective roads in the development of generic enoxaparin (add in a specific question to the Plaintiff and an extended TRO)...

IMO the weight of evidence will fall to the favor of Momenta and the Judge will be grant the PI.
May be wishful thinking on my part but I am looking forward to an end of the roller-coaster... and (finally) market realization of MNTA's strengths.